LivingGLP1
parallel randomized trial

S002930

Design

Randomized
34
Start year
Treatment
52 weeks, follow-up 52 weeks
Countries
Hungary (1 sites)
Sponsor
(non industry)
Eligibility
age over 45; T2DM at least 5 years; HbA1c 6.5 to 10 percent; BMI above 25; eGFR above 60

Conduct and analysis

Blinding
not reported
Sequence generation
not reported
Allocation concealment
not reported
Outcome adjudication
not reported
Primary estimand
not stated
Analysis population
Missing data

Arms

ArmTreatmentBackgroundRandomizedAnalyzedCompleted treatment
A1Semaglutide 1.0 mg subcutaneous once weekly
Semaglutide 1 mg weekly
metformin and statin; lifestyle: not reported18
A2Sitagliptin
Sitagliptin 100 mg daily
metformin and statin; lifestyle: not reported16

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.
CharacteristicStatisticSemaglutide 1.0 mg subcutaneous once weekly
A1
Sitagliptin
A2
agemean (years)57.959.4
agesd (years)10.611.9
bmimean (kg/m2)37.9631.26
bmisd (kg/m2)10.642.75
diabetes durationmean (years)8.49.6
diabetes durationsd (years)3.63.2
egfrmedian (mL/min/1.73 m2)8790
egfrq1 (mL/min/1.73 m2)7473
egfrq3 (mL/min/1.73 m2)9090
femalen69
hba1cmean (percent)8.088.13
hba1csd (percent)1.651.29
waistmean (cm)126.4126.6
waistsd (cm)21.825.1

Results

6 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
HbA1c change (5 lines; O01)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
26A1final6.86 percent1.12not stated; other; R0004797:Table 2
26A2final6.91 percent0.95not stated; other; R0004797:Table 3
52A1change-1.5 percentnot stated; other; R0004797:Results
52A1final6.57 percent0.95not stated; other; R0004797:Table 2
52A2final7.11 percent1.07not stated; other; R0004797:Table 3
Percent body weight change (1 lines; O10)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
52A1percent change-8.1 percentnot stated; other; R0004797:Results